Vaxart, Inc. (VXRT) has experienced a rise of 10.72% after the New Duke University-led Study Shows That Vaxart’s Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection. However, the last trading session closed at $7.09 with a decrease of 0.14%.
Vaxart’s Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model
On 7th October 2021, VXRT announced the research headed by Duke University. The experiment showed that oral tablet vaccination decreased the airborne transmission of the SARS-CoV-2 virus. Moreover, these findings are in line with Vaxart’s Phase II human flu challenge trial. This found that the oral tablet vaccination was more effective than the injectable flu vaccine comparator at decreasing shedding.
Airborne transmission occurs in persons who have received COVID-19 vaccinations. Lastly, Vaxart’s oral vaccination platform also elicited significant systemic and mucosal responses in the preclinical research.
VXRT Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
VXRT reported on 6th October 2021 that the Phase II COVID-19 oral tablet vaccination clinical study is now recruiting participants. Later this month, Vaxart plans to start administering the first of 96 U.S. participants, who will be split evenly between COVID-19 naive, and mRNA vaccinated. The Phase II COVID-19 initiative will also include countries outside of the United States.
In addition, Phase II represents a critical step in the development of the first and only COVID-19 oral tablet vaccine to reach this stage. An oral vaccination has the potential to significantly enhance global public health and the worldwide response to the COVID-19 pandemic. It can be quicker and faster to administer than injectables.
Appointment of Chief Medical Officer
On 27th September 2021, VXRT announced that James F. Cummings, M.D. is the Chief Medical Officer of the Company (CMO). Dr. Cummings is a board-certified infectious disease physician with considerable experience in developing vaccines, drugs, and diagnostics. He joins VXRT as the company plans to launch COVID-19 oral tablet Phase II clinical trials.
His clinical trial experience, vaccine development knowledge, and extensive industry network will aid VXRT in achieving its strategic goals as we create novel solutions to enhance global public health through oral tablet vaccinations. The company is thrilled to have Dr. Cummings’ on board at this critical juncture in our COVID-19 and norovirus vaccine late-stage clinical trials. He can help the company by leading the expanding portfolio of oral vaccine candidates.
